 This study is a post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLSrestless leg syndrome and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of ropinirole in real clinical practices after marketing. The subjects are patients prescribed for ropinirole by the investigators at the sites based on prescription information in normal clinical practices. 